<DOC>
	<DOCNO>NCT01279967</DOCNO>
	<brief_summary>To examine whether arginine deplete drug , ADI-PEG 20 , might effective targeted therapy patient ASS-negative malignant pleural mesothelioma .</brief_summary>
	<brief_title>A Clinical Trial ADI-PEG 20TM Patients With Malignant Pleural Mesothelioma</brief_title>
	<detailed_description />
	<mesh_term>Mesothelioma</mesh_term>
	<criteria>1 . Males Females age 18 year old . ( There upper age limit ) 2 . Histopathological evidence ASSnegative MPM . All biopsy review ASS expression use immunohistochemistry . Central lab confirmation require randomization 3 . Performance status ECOG â‰¤ 1 . Life expectancy great 3 month 4 . Chemonaive patient OR , Patients previously treat platinumbased combination chemotherapy progressive disease entry . In event baseline diagnostic ASSpositive test , repeat biopsy confirm loss ASS expression require post platinumbased combination chemotherapy , least 4 week interval last treatment episode . 5 . CT evaluable disease modify RECIST criterion 6 . Adequate bone marrow function , support treatment : Haemoglobin 10g/dl great . White cell count 2 x 109/L great , neutrophil count 1.5 x 109/L great Platelets 75 x 109 /L great . 7 . Adequate hepatic function ( AST ALT &lt; 3 x upper limit normal ; bilirubin &lt; 1.5 x upper limit normal ) 8 . Creatinine clearance &gt; 30ml/min 9 . Able give write informed consent participate 1 . Participation another clinical trial use investigational agent 2 . Patients surgically resectable disease 3 . Recurrent pleural effusion ( pleurodesed ) 4 . Receipt extensive radiation ( hemithorax ) therapy within 6 week enrollment . Radiation chest port site follow thoracotomy permit 5 . A history prior malignant tumour , unless patient without evidence disease least three year , tumour nonmelanoma skin tumour insitu cervix carcinoma 6 . Symptomatic know brain leptomeningeal metastases 7 . Uncontrolled severe cardiovascular disease include myocardial infarction within 6 month enrollment 8 . New York Heart Association ( NYHA ) Class III IV heart failure ( Attachment 10 , NYHA Classification Cardiac Disease ) , uncontrolled angina , clinically significant pericardial disease , cardiac amyloidosis 9 . Serious medical ( e.g . uncontrolled diabetes , hepatic disease , infection , uncontrolled gout ) psychiatric illness likely interfere participation clinical study 10 . History seizures 11 . Patients childbearing age must become pregnant . Females childbearing potential must negative pregnancy test within 7 day prior register protocol therapy . All patient enrol study must agree use acceptable birth control measure whilst study ; use barrier hormonal method . Patients surgically sterile also eligible participate study 12 . Females must breastfeed 13 . Prior exposure ADIPEG 20 14 . Preplanned surgery procedure would interfere study protocol 15 . Allergy pegylated product 16 . Exposure another investigational drug within 4 week prior start study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Pleural Mesothelioma</keyword>
	<keyword>ADI-PEG 20</keyword>
</DOC>